检索结果-南通市图书馆

Hepatocellular carcinoma staging systems: Hong Kong liver cancer vs Barcelona clinic liver cancer in a Western population

引用

World Journal of Hepatology 2019年第9期11卷 678-688页

作者： Laura Bainy Rodrigues de Freitas Larisse Longo deivid santos Ivana Grivicich Mário Reis Alvares-da-Silva Graduate Program in Gastroenterology and Hepatology Universidade Federal do Rio Grande do SulPorto AlegreRS 90035-003Brazil Experimental Hepatology and Gastroenterology Laboratory Center for Experimental ResearchHospital de Clínicas de Porto AlegrePorto AlegreRS 90035-003Brazil School of Medicine Universidade Federal do Rio Grande do SulPorto AlegreRS 90035-003Brazil Graduate Program in Health-Applied Cellular and Molecular Biology ULBRA.CanoasRS 92425-900Brazil Department of Gastroenterology Hospital de Clínicas de Porto AlegrePorto AlegreRS 90035-003Brazil

BACKGROUND Despite being the world’s most widely used system for staging and therapeutic guidance in hepatocellular carcinoma(HCC)treatment,the Barcelona clinic liver cancer(BCLC)system has limitations,especially regarding intermediate-grade(BCLC-B)*** recently proposed Hong Kong liver cancer(HKLC)staging system appears useful but requires validation in Western *** To evaluate the agreement between BCLC and HKLC staging on the management of HCC in a Western population,estimating the overall patient *** This was a retrospective study of HCC patients treated at a university hospital in southern Brazil between 2011 and ***,clinical,and laboratory data were *** staging was carried out according to the HKLC and BCLC systems to assess treatment *** survival was estimated based on the treatment proposed in each *** A total of 519 HCC patients were *** these,178(34.3%)were HKLC-I;95(18.3%)HKLC-IIA;47(9.1%)HKLC-IIB;29(5.6%)HKLC-IIIA;30(5.8%)HKLCIIIB;75(14.4%)HKLC-IV;and 65(12.5%)*** to the BCLC,25(4.9%)were BCLC-0;246(47.4%)BCLC-A;107(20.6%)BCLC-B;76(14.6%)BCLCC;and 65(12.5%)*** general agreement between the two systems was 80.0%-BCLC-0 and HKLC-I(100%);BCLC-A and HKLC-I/HKLC-II(96.7%);BCLC-B and HKLC-III(46.7%);BCLC-C and HKLC-IV(98.7%);BCLC-D and HKLC-V(41.5%).When sub-classifying BCLC-A,HKLC-IIB,HKLC-IIIA and HKLC-IIIB stages according to the up-to-7 in/out criterion,13.4,66.0,100 and 36.7%,respectively,of the cases were classified as up-to-7 *** In a Western population,the general agreement between the two systems was 80.0%,although in BCLC-B cases the agreement was low,suggesting that some individuals could be candidates for the curative treatment recommended by the *** authors suggest that the BCLC system should be routinely employed,although for BCLC-B cases it should be associated with the HKLC system.

关键词： Barcelona clinic liver cancer staging system Hepatocellular carcinoma Hong Kong liver cancer staging system

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Association of interferon lambda-4 rs12979860 polymorphism with hepatocellular carcinoma in patients with chronic hepatitis C infection

引用

World Journal of Hepatology 2021年第1期13卷 109-119页

作者： Jóice Teixeira de Bitencorte Tássia Flores Rech Vagner Ricardo Lunge deivid Cruz dos santos Mário ReisÁlvares-da-Silva Daniel Simon PPG Biologia Celular e Molecular AplicadaàSaúde Universidade Luterana do BrasilCanoas 92425-900Rio Grande do SulBrazil Division of Gastroenterology Hospital de Clínicas de Porto AlegrePorto Alegre 90035-903Rio Grande do SulBrazil

BACKGROUND Hepatitis C virus(HCV)infection is a public health concern *** factors,including genetic polymorphisms,may be evolved in the progression of HCV infection to liver *** lambdas(IFNLs)modulate the immune response during viral *** induce antiviral activity,interfering in the viral replication by promoting the expression of several genes that regulate immunological *** interferon lambda-4(IFNL4)rs12979860 polymorphism,which is characterized by a C to T transition in intron 1,is associated with spontaneous and treatment-induced clearance of HCV infection and may play a role in the development of HCV-associated liver diseases,including hepatocellular carcinoma(HCC).AIM To investigate the association of IFNL4 rs12979860 polymorphism with fibrosis,cirrhosis,and HCC in patients with chronic HCV *** This study was comprised of 305 chronic HCV-infected patients(53 fibrosis,154 cirrhosis,and 98 HCC cases).The control group was comprised of 260 HCVnegative healthy *** IFNL4 rs12979860 polymorphism was genotyped using the TaqMan *** was diagnosed based on liver biopsy findings,while cirrhosis was diagnosed through clinical,laboratory,anatomopathological,and/or imaging *** was diagnosed through imaging tests,tumor,and/or anatomopathological *** The T allele was observed in the three groups of patients(fibrosis,cirrhosis,and HCC)at a significantly higher frequency when compared with the control group(P=0.047,P<0.001,and P=0.01,respectively).Also,genotype frequencies presented significant differences between the control group and cirrhosis patients(P<0.001)as well as HCC patients(P=0.002).The risk analysis was performed using the codominant and dominant T allele *** the codominant model,it was observed that the CT genotype showed an increased risk of developing cirrhosis in comparison with the CC genotype[odds ratio(OR)=2.53;95%confidence interval(CI):1.55-4.15;

关键词： Hepatitis C Hepatitis C virus Cirrhosis Hepatocellular carcinoma Genetic polymorphism Interferon-lambda

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：